Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Research

• Publication date

  1996-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 8616854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE CLASSIC: Amputation and Adriamycin in Primary Osteosarcoma

  2005cited by this paper
• Development of a model of melphalan-induced gastrointestinal toxicity in mice

  2004cited by this paper
• Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.

  1994cited by this paper
• Protection against doxorubicin‐induced alopecia in rats by liposome‐entrapped monoclonal antibodies

  1994cited by this paper
• Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993.

  1994cited by this paper
• Systemic and Topical Immunoglobulin Treatment in Immunocompromised Patients

  1994cited by this paper
• Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview.

  1993cited by this paper
• Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy?

  1993cited by this paper
• Abrogation of adriamycin toxicity in vivo by cycloheximide.

  1992cited by this paper
• The nature of cytotoxic drug-induced cell death in murine intestinal crypts.

  1992cited by this paper
• An anti‐doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug

  1992cited by this paper
• Current research in side effects of high-dose chemotherapy.

  1992cited by this paper
• Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea.

  1991cited by this paper
• Anti‐drug monoclonal antibodies antagonize toxic effect more than anti‐tumor activity of doxorubicin

  1991cited by this paper
• Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.

  1991cited by this paper
• The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

  1989cited by this paper
• Managing the side effects of chemotherapy.

  1989cited by this paper
• A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

  1988cited by this paper
• Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis.

  1985cited by this paper
• Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

  1982cited by this paper
• A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus.

  1982cited by this paper
• Survival of Oral Human Immune Serum Globulin in the Gastrointestinal Tract of Low Birth Weight Infants

  1981cited by this paper
• Amputation and adriamycin in primary osteosarcoma: a 5-year report.

  1978cited by this paper
• Antitumor antibiotics.

  1961cited by this paper
• For April.

  1903cited by this paper

• Perilous consequences of chemotherapy induced alopecia in afflicted cancer survivors: a comprehensive state of the art review

  2024cites this paper
• Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model.

  2023cites this paper
• Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models

  2022cites this paper
• Oral Supramolecular Adsorbent for Preventing Chemo‐Induced Gastrointestinal Mucositis and Microbial Dysbiosis and for Enhancing Chemoimmunotherapy

  2022cites this paper
• Peptidoglycan Recognition Peptide 2 Aggravates Weight Loss in a Murine Model of Chemotherapy-Induced Gastrointestinal Toxicity

  2021cites this paper
• Layered self-assemblies for controlled drug delivery: A translational overview.

  2020cites this paper
• Enzyme/pH-triggered anticancer drug delivery of chondroitin sulfate modified doxorubicin nanocrystal

  2020cites this paper
• Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring

  2020cites this paper
• An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery

  2019cites this paper
• Carbon Nanomaterials for Photothermal Therapies

  2018cites this paper
• Janus Gold Nanoplatform for Synergetic Chemoradiotherapy and Computed Tomography Imaging of Hepatocellular Carcinoma.

  2017cites this paper
• Ingenious pH-sensitive dextran/mesoporous silica nanoparticles based drug delivery systems for controlled intracellular drug release.

  2017cites this paper
• Doxorubicin inhibits muscle inflammation after eccentric exercise

  2016cites this paper
• Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats

  2016cites this paper
• Combination Treatment of Murine Colon Cancer with Doxorubicin and Redox Nanoparticles.

  2016cites this paper
• Janus "nano-bullets" for magnetic targeting liver cancer chemotherapy.

  2016cites this paper
• Facile Synthesis of Core–shell Magnetic Mesoporous Silica Nanoparticles for pH‐sensitive Anticancer Drug Delivery

  2015cites this paper
• Fluorescent porous carbon nanocapsules for two-photon imaging, NIR/pH dual-responsive drug carrier, and photothermal therapy.

  2015cites this paper
• Structure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugs.

  2015cites this paper
• pH-Responsive Capsules Engineered from Metal-Phenolic Networks for Anticancer Drug Delivery.

  2015cites this paper
• Protective effects of silymarin on epirubicin-induced mucosal barrier injury of the gastrointestinal tract

  2015cites this paper
• Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications

  2015cites this paper
• Tumor-targeting glycol chitosan nanoparticles as a platform delivery carrier in cancer diagnosis and therapy.

  2014cites this paper
• Iron-Loaded Magnetic Nanocapsules for pH-Triggered Drug Release and MRI Imaging

  2014cites this paper
• Potential of long-chain n-3 polyunsaturated fatty acids in melanoma prevention.

  2014cites this paper
• SPARC, a matricellular protein that protects cancer from therapy

  2014cites this paper
• Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence.

  2013cites this paper
• Polymeric micelles with π-π conjugated cinnamic acid as lipophilic moieties for doxorubicin delivery.

  2013cites this paper
• pH-controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres.

  2012cites this paper
• Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis

  2012cites this paper
• Interaction of single-walled nanotubes with doxorubicin and poly(ethylene glycol) according to the molecular docking method

  2011cites this paper
• Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin.

  2011cites this paper
• A tumor mRNA-dependent gold nanoparticle-molecular beacon carrier for controlled drug release and intracellular imaging.

  2011cites this paper
• Overview on the Major Research Activities on Carbon Nanotubes Being Done in America, Europe and Asia

  2011cites this paper
• Doxycycline suppresses doxorubicin-induced oxidative stress and cellular apoptosis in mouse hearts.

  2010influential citation
• Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy.

  2009cites this paper
• Alimentary tract mucositis: NF-kB and pro-inflammatory cytokines in the tissues and serum following chemotherapy.

  2008cites this paper
• Establishment of a Single-Dose Irinotecan Model of Gastrointestinal Mucositis

  2007cites this paper
• The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs.

  2007cites this paper
• Mucosal injury from targeted anti-cancer therapy

  2007influential citation
• Irinotecan changes gene expression in the small intestine of the rat with breast cancer

  2006cites this paper
• Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage

  2006cites this paper
• A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat

  2006cites this paper
• Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies

  2006cites this paper
• Salubrious effects of lipoic acid against adriamycin-induced clastogenesis and apoptosis in Wistar rat bone marrow cells.

  2006cites this paper
• Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat

  2005cites this paper
• Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats.

  2004cites this paper
• Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin

  2003cites this paper
• Colloidal anticancer drugs bioavailabilities in oral administration models.

  2003cites this paper
• Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice

  2001cites this paper
• Antitumour activity and adverse reactions of combined treatment with chitosan and doxorubicin in tumour‐bearing mice

  2001cites this paper
• Clarithromycin attenuates cyclophosphamide-induced mucositis in mice.

  2000cites this paper
• Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures.

  1999cites this paper
• Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis.

  1999cites this paper
• Effects of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells.

  1998cites this paper
• Monoclonal antibodies to taxanes that neutralize the biological activity of paclitaxel.

  1998cites this paper
• Anthracyclines in haematology: preclinical studies, toxicity and delivery systems.

  1997cites this paper
• Breast Cancer Therapies in Development

  1997cites this paper
• Oral Delivery of Antibodies

  1997cites this paper
• Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice.

  1997cites this paper
• Breast cancer therapies in development. A review of their pharmacology and clinical potential.

  1997cites this paper